Introduction
Medical innovation moves quickly. New medications, surgical techniques, medical devices, gene therapies and other treatments can become available before every health insurance policy has established broad coverage for them.
That creates a difficult question for patients:
Can your health insurance company refuse to pay because it considers your treatment experimental or investigational?
The short answer is:
Yes, in some circumstances.
A health plan may deny coverage when it determines that a treatment falls under an applicable experimental or investigational exclusion or fails the plan’s coverage criteria.
However, a denial doesn’t necessarily end the matter.
HealthCare.gov specifically identifies an insurer’s determination that treatment is experimental or investigational as a type of decision that can qualify for both internal appeal and, depending on the applicable process, independent external review.
Understanding the difference between an uncovered experimental treatment and a treatment that may have been incorrectly classified can be critical.
What Does “Experimental Treatment” Mean?
There isn’t one simple definition that applies identically to every health insurance policy.
Insurers may use terms such as:
Experimental
Investigational
Unproven
or:
Not medically necessary.
Your plan documents should explain how these terms affect coverage.
A plan may evaluate factors such as:
- Regulatory status
- Published clinical evidence
- Medical literature
- Professional guidelines
- Treatment outcomes
- Accepted standards of medical practice
- Whether sufficient evidence demonstrates effectiveness
- Whether the treatment is appropriate for your specific condition
This is why two treatments that sound similarly “new” can receive completely different coverage decisions.
Experimental Doesn’t Always Mean Unsafe
This distinction is important.
When an insurance company labels treatment:
Experimental or investigational
it doesn’t necessarily mean the insurer has concluded that the treatment is dangerous.
The issue may instead be whether the treatment satisfies the plan’s particular criteria for:
coverage.
For example, there may be evidence that a therapy works for one condition but less evidence supporting its use for another.
That can lead to different insurance decisions involving the same medication or procedure.
FDA Approval Doesn’t Automatically Guarantee Insurance Coverage
Suppose the FDA approves a new drug.
Does that automatically mean your health insurance must pay for it?
Not necessarily.
Regulatory approval and insurance coverage are different decisions.
A health plan may still apply:
Medical-necessity criteria
Formulary requirements
Prior authorization
Step therapy
Network rules
and other applicable coverage requirements.
Similarly, lack of ordinary FDA approval doesn’t automatically mean every associated healthcare service is excluded in every circumstance.
Coverage can be more complicated, particularly in approved clinical trials and certain Medicare research settings.
Why Would an Insurer Deny an Experimental Treatment?
There are several possible reasons.
1. Insufficient Clinical Evidence
An insurer may conclude there isn’t enough high-quality evidence demonstrating that the treatment is effective for:
your particular medical condition.
This can be especially relevant to newly developed treatments.
2. Treatment Is Being Used for a Different Condition
A medication may be well established for one disease but proposed for another.
That can create a dispute over whether the proposed use satisfies the plan’s coverage criteria.
3. The Plan Contains an Experimental-Treatment Exclusion
Your policy may specifically exclude certain treatments classified as:
experimental or investigational.
The important question then becomes:
Was your treatment correctly classified under that definition?
That can be challenged through the appeals process.
4. Medical Necessity Hasn’t Been Established
Sometimes the denial isn’t simply:
“This treatment is experimental.”
Instead, the insurer may determine that the treatment isn’t:
medically necessary
for your particular situation.
Medical-necessity decisions are also among the types of decisions that can be subject to external review.
5. Required Prior Authorization Wasn’t Obtained
A cutting-edge treatment can require extensive preauthorization.
Even if the treatment could potentially qualify for coverage, failure to complete the plan’s authorization requirements can create another coverage problem.
Always distinguish:
Experimental-treatment denial
from:
Prior-authorization denial.
Your appeal strategy may differ.
Example: A New Cancer Therapy
Imagine a patient has an advanced cancer.
Standard treatments haven’t produced the desired result.
The patient’s oncologist recommends a newer therapy based on:
Recent research
Clinical evidence
and:
The patient’s specific medical history.
The insurer denies authorization, stating:
“Experimental/Investigational.”
The patient shouldn’t assume:
“There’s nothing else I can do.”
Instead, the patient and physician should determine:
Why did the insurer classify it as experimental?
Which policy provision applies?
What clinical evidence did the insurer consider?
Does newer evidence support the treatment?
Does the patient’s medical situation satisfy an exception?
Those questions can form the foundation of an appeal.
Your Insurer Must Explain the Denial
For plans subject to applicable federal claims rules, a denial cannot simply amount to:
“No.”
The U.S. Department of Labor explains that health-plan denial notices generally must provide specific reasons and identify relevant plan provisions. When a denial relies on medical necessity or an experimental-treatment exclusion, the notice must also provide the scientific or clinical judgment used—or state that such an explanation will be provided free upon request.
That information can be extremely useful.
It tells your physician:
what argument needs to be challenged.
Step 1: Read the Denial Letter Carefully
Look for the exact terminology.
Does it say:
Experimental?
Investigational?
Not medically necessary?
Not a covered benefit?
Prior authorization denied?
Insufficient clinical evidence?
Don’t treat these as interchangeable.
Identify the precise reason.
Step 2: Find the Definition in Your Policy
Request or review your:
Summary of Benefits and Coverage
and, when necessary:
full plan document.
Search for:
Experimental
Investigational
Medical necessity
Clinical trials
and:
Exclusions.
Compare the insurer’s decision with the actual policy definition.
The key question isn’t merely:
“Is this treatment new?”
It’s:
“Does this treatment actually meet my plan’s definition of experimental or investigational?”
Step 3: Ask for the Criteria Used
If the insurer relied on an internal:
Guideline
Clinical policy
Medical protocol
or:
Coverage standard,
request the relevant information you’re entitled to receive.
For ERISA-covered group health plans, the Department of Labor says denial notices based on rules, guidelines or protocols must describe them or explain that a copy will be provided without charge upon request.
This can help your physician determine where the insurer’s reasoning may be outdated or incomplete.
Step 4: Get Your Doctor Involved
Your treating physician can be one of the most important participants in an experimental-treatment appeal.
Ask your doctor to explain:
Your diagnosis
Disease severity
Treatments already attempted
Why standard alternatives failed or are inappropriate
Why the proposed treatment is medically appropriate
Evidence supporting its use
and:
Risks of delaying treatment.
The appeal should be specific to:
you.
A pile of research papers without an explanation of how they apply to your medical situation may be less persuasive than a well-organized clinical argument.
Step 5: Gather Strong Medical Evidence
Depending on the treatment, supporting evidence might include:
Peer-reviewed studies
Randomized clinical trials
Systematic reviews
Professional medical-society guidelines
FDA materials
Specialist recommendations
Treatment history
and:
Relevant medical records.
Focus on reliable, current evidence.
A physician can help identify which studies are most relevant.
Step 6: File an Internal Appeal
Federal consumer protections provide internal appeal rights for many health-plan denials.
HealthCare.gov specifically lists a requested treatment classified as:
“experimental” or “investigative”
among the denials that may be internally appealed.
Under the federal process described by HealthCare.gov, you generally have:
180 days
from receiving the denial notice to file an internal appeal.
Always follow the specific deadline and instructions in your denial notice because procedures can vary by plan.
What Should Your Appeal Include?
A strong appeal package might contain:
Patient information
Insurance identification
Claim or authorization number
Treatment requested
Original denial letter
Relevant policy provisions
Doctor’s medical-necessity letter
Medical records
Previous treatments and outcomes
Clinical studies
Professional guidelines
and:
A clear request to reverse the denial.
Keep copies of everything you submit.
HealthCare.gov also recommends keeping records of relevant communications, including dates, names and details of conversations with the insurer and medical providers.
What If the Internal Appeal Is Denied?
This is where experimental-treatment disputes have an important protection.
You may qualify for:
External Review.
Instead of asking the insurance company to evaluate itself again, an independent reviewer examines the dispute.
HealthCare.gov specifically states that a denial based on a determination that treatment is experimental or investigational is among the types of decisions eligible for external review under applicable processes.
If the external reviewer overturns the insurer’s decision, the insurer must accept the external review decision.
Why External Review Can Matter
Imagine your insurer’s clinical policy was written before several important studies were published.
Your doctor submits:
New clinical evidence
Specialist recommendations
and:
Your treatment history.
The insurer maintains its denial.
An independent medical reviewer may then examine whether the insurer’s experimental classification is justified based on the evidence and applicable coverage terms.
External review means:
the insurer doesn’t necessarily have the final word.
How Long Do You Have to Request External Review?
HealthCare.gov currently states that a written request for external review generally must be filed within:
Four months
after receiving the applicable notice or final determination.
Your denial notice should explain:
Whether you’re eligible
Where to file
and:
Your deadline.
Follow those instructions carefully.
What If Treatment Is Urgently Needed?
Some medical situations can’t safely wait through a lengthy standard appeal.
If following the ordinary appeals timeline could seriously jeopardize your:
Life
Health
or:
Ability to regain maximum function,
an expedited process may be available.
HealthCare.gov states that qualifying urgent situations may permit an external review even before all internal appeal steps are completed.
For eligible expedited external reviews, a decision must generally be issued as quickly as the medical condition requires and no later than 72 hours after the request is received.
If the situation is urgent, tell both:
your physician
and:
your insurer
immediately.
Experimental Treatment vs. Clinical Trial
These concepts shouldn’t automatically be treated as the same thing.
A patient participating in a clinical trial may receive:
Experimental treatment
alongside:
Routine medical care.
Federal rules can provide protections involving certain routine patient costs associated with participation in approved clinical trials, depending on the plan and circumstances.
That doesn’t necessarily mean your insurer must pay for:
the investigational drug or device itself.
The coverage analysis can differ between:
Routine care
and:
The experimental intervention.
Medicare Has Special Rules Too
Medicare coverage for investigational treatment can follow different rules from ordinary private insurance.
For example, CMS explains that certain routine care items and services furnished in qualifying Investigational Device Exemption studies can receive Medicare coverage, while a Category A experimental device itself is statutorily excluded from coverage.
So Medicare beneficiaries shouldn’t assume that the rules governing an employer or Marketplace plan apply identically to Medicare.
Employer Health Plans Can Be Different
If your insurance comes through your employer, determine whether the plan is:
Fully insured
or:
Self-funded.
For many employer plans governed by ERISA, federal claims and appeals rules are especially relevant.
The Department of Labor states that when a group health-plan denial concerns whether a treatment or drug is experimental, investigational or medically necessary, the appeal reviewer must consult with an appropriately qualified healthcare professional.
Your HR or benefits department can help identify your plan type and obtain the full plan documents.
Mental Health Treatment Must Also Be Considered Carefully
Experimental-treatment exclusions can also raise mental-health parity issues.
The Department of Labor has explained that a plan cannot apply an experimental or investigational treatment limitation to mental-health or substance-use-disorder benefits more stringently than comparable medical/surgical benefits when federal parity requirements apply.
This can become relevant when an insurer covers exceptions for emerging medical treatments but applies a materially stricter approach to comparable behavioral-health treatment.
Five Mistakes to Avoid After a Denial
1. Assuming the first denial is final
Experimental-treatment determinations can be appealed.
2. Appealing without your physician
Clinical expertise and individualized medical evidence can be critical.
3. Sending only emotional arguments
Explain why the treatment satisfies the policy’s coverage criteria.
4. Ignoring newer research
A plan’s clinical policy may not necessarily reflect the newest evidence.
5. Missing appeal deadlines
Even a medically strong appeal can become much harder if you miss required filing deadlines.
Experimental Treatment Appeal Checklist
When your insurer denies treatment as experimental or investigational:
- Read the complete denial notice.
- Identify the exact reason for denial.
- Find the relevant provision in your health plan.
- Request the insurer’s clinical criteria or guideline.
- Ask for the scientific or clinical reasoning behind the decision.
- Contact your treating physician.
- Obtain a detailed medical-necessity letter.
- Document treatments you’ve already tried.
- Gather relevant medical records.
- Collect strong peer-reviewed clinical evidence.
- Include applicable professional guidelines.
- File the internal appeal before the deadline.
- Keep copies of everything.
- Request expedited review if medically urgent.
- Review external-review rights if the denial is upheld.
- Check the deadline for external review.
- Contact your state insurance department or Consumer Assistance Program if you need help.
Frequently Asked Questions
Can health insurance refuse to cover experimental treatment?
Yes. A health plan may deny treatment under an applicable experimental or investigational exclusion or coverage standard. However, such a determination can be appealable.
Can I appeal an experimental-treatment denial?
Yes. HealthCare.gov specifically identifies experimental or investigational treatment decisions as a category that can be challenged through the appeals process.
Can an independent reviewer overturn the insurance company?
Yes, for an eligible external review. The reviewer can uphold or overturn all or part of the insurer’s decision, and the insurer must accept the external reviewer’s determination.
Does FDA approval guarantee insurance coverage?
No. FDA approval doesn’t automatically guarantee payment under every health plan. Coverage can still depend on the plan’s benefits, medical-necessity rules, prior authorization and other requirements.
Can my doctor help with the appeal?
Yes. A detailed physician letter explaining why the treatment is medically appropriate and addressing the insurer’s stated reason for denial can be valuable. HealthCare.gov specifically identifies information from your doctor as documentation that may accompany an internal appeal.
What happens if my treatment can’t wait?
Ask about an expedited appeal or external review. Qualifying urgent cases can receive faster review, and in some circumstances internal and external review can proceed simultaneously.
How long do I have to appeal?
Under the federal process described by HealthCare.gov, internal appeals generally must be filed within 180 days of receiving the denial. External review generally must be requested within four months of the applicable denial/final determination. Follow the instructions and deadlines in your own notice.
Final Thoughts
Your health insurer can potentially deny coverage for a treatment it considers experimental or investigational.
But:
“Experimental” doesn’t necessarily mean “case closed.”
The most important question is whether the treatment was correctly classified under your plan’s terms and applicable law.
If your insurer denies coverage:
Find the exact reason.
Read the policy definition.
Request the clinical criteria.
Involve your physician.
Gather strong medical evidence.
File an internal appeal.
And if the insurer maintains an eligible experimental-treatment denial:
Consider independent external review.
Federal consumer protections specifically recognize experimental and investigational treatment determinations as an important category for external review.
For someone facing a serious medical condition, that independent review can be one of the most important protections available when a health plan and treating physician disagree about an emerging treatment.
Disclaimer
This article is for informational and educational purposes only and isn’t medical, legal, financial or insurance advice. Coverage requirements, exclusions, appeals and external-review rights vary by health plan, employer, state and individual circumstances. Patients should consult their healthcare provider, insurer and qualified legal or insurance professionals when appropriate.